Dursun P.Erkanli S.Güzel A.B.Gultekin M.Tarhan N.C.Altundag O.Demirkiran F.Beşe T.Yildirim Y.Bozdag G.Yarali H.Simsek T.Ozcelik B.Ortaç F.Taskin S.Guvenal T.Ozgul N.Haberal A.Vardar M.A.Dede M.Yenen M.Altintas A.Arvas M.Ayhan A.2024-07-222024-07-22201200207292http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17848Objective: To analyze the results of fertility-sparing treatment of early-stage endometrial cancer (EC) in patients treated at Turkish gynecologic oncology centers, and to present a review of the literature. Methods: Thirteen healthcare centers in Turkey were contacted to determine if they were eligible to participate in the study. Centers that were eligible and agreed to participate were sent a database form to record the demographic characteristics, clinicopathologic findings, and follow-up results for their EC patients. Results: Eleven Turkish healthcare centers provided data on 43 EC patients. Mean duration of treatment was 5 months and mean follow-up was 49 months. In total, 35 (81.4%) patients were tumor free following primary progesterone therapy. Mean time from the end of progesterone therapy to pregnancy was 10.6 ± 4.3 months (range, 3-18 months). Two patients had tumor recurrence during follow-up. The pregnancy rate among the 31 women who actively sought pregnancy was 41.9% (n = 13). Conclusion: Conservative management of early-stage EC in women of reproductive age using oral progestins was effective and did not compromise oncological outcome. Pregnancy in the study patients was achieved spontaneously and artificially. © 2012 International Federation of Gynecology and Obstetrics.Englishmedroxyprogesterone acetatemegestrol acetateadultcancer chemotherapyclinical articleconference paperdrug efficacyendometrium cancerfemalefemale fertilityfertility sparing treatmenthumanpregnancy ratepriority journaltreatment durationtreatment outcomeTurkey (republic)Conference paper10.1016/j.ijgo.2012.06.010